Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariate analyses, the number of DRV resistance-associated mutations depended on the number of previous protease inhibitors (PIs) administered and on amprenavir/fosamprenavir treatment. Most PI-treated patients should respond favorably to DRV-based salvage therapy.
Mitsuya
Yumi
Y
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Liu
Tommy F
TF
Rhee
Soo-Yon
SY
Fessel
W Jeffrey
WJ
Shafer
Robert W
RW
D002140:California / Q000453:epidemiology; D000069454:Darunavir; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D015658:HIV Infections / Q000453:epidemiology / Q000235:genetics*; D016333:HIV Protease / Q000235:genetics; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D015995:Prevalence; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
D011480:Protease Inhibitors; D013449:Sulfonamides; D016333:HIV Protease; D000069454:Darunavir